Novo Nordisk A/S Common Stock (NVO)

Total Costs & Expenses

kr 51.43B

Quarterly · Period ending: · DKK

NVO logo

NVO Total Costs & Expenses

Latest reportedkr 51.43B DKK
NVO Quarterly Total Costs & Expenses · DKK (kr 985.86M → kr 51.43B)
High-resolution chart · PNG

NVO total costs & expenses history

Quarterly · DKK. Dates are reporting period ends; fiscal years can differ from calendar years.

Novo Nordisk A/S Common Stock Total Costs & Expenses — Quarterly (DKK)
Period endingTotal Costs & Expenses (DKK)
51,427,000,000
37,205,000,000
47,408,000,000
51,294,000,000
43,408,000,000
39,296,000,000
48,946,000,000
37,489,000,000
42,126,000,000
33,503,000,000
39,097,000,000
31,818,000,000
30,412,000,000
28,360,000,000
31,005,000,000
25,382,000,000
22,874,000,000
22,884,000,000
24,699,000,000
20,373,000,000
18,262,000,000
18,822,000,000
20,960,000,000
18,119,000,000
16,168,000,000
17,573,000,000
20,544,000,000
17,358,000,000
16,584,000,000
15,052,000,000
18,949,000,000
15,949,000,000
15,203,000,000
14,482,000,000
17,945,000,000
14,570,000,000
15,252,000,000
14,962,000,000
18,366,000,000
15,117,000,000
14,962,000,000
14,903,000,000
17,751,000,000
14,812,000,000
14,577,000,000
11,343,000,000
15,428,000,000
13,680,000,000
12,896,000,000
12,310,000,000
14,344,000,000
12,519,000,000
12,795,000,000
12,421,000,000
13,390,000,000
11,981,000,000
11,815,000,000
11,366,000,000
12,039,000,000
10,922,000,000
10,736,000,000
10,275,000,000
11,780,000,000
10,460,000,000
10,353,000,000
9,292,000,000
9,843,000,000
8,703,000,000
8,911,000,000
8,688,000,000
9,310,458,000
7,922,000,000
8,265,339,000
7,785,000,000
9,874,173,500
7,818,981,000
7,756,199,000
7,489,675,000
8,380,044,000
7,081,940,000
7,098,522,000
7,067,260,000
7,481,813,000
6,482,240,000
5,932,890,000
5,753,057,000
6,165,514,000
5,649,264,000
5,283,056,000
5,020,894,000
5,431,789,000
5,076,691,000
4,875,292,000
4,771,662,000
6,682,043,000
6,445,668,000
5,278,480,000
6,020,344,000
6,503,165,000
6,652,112,000
Data is provided for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results.